Prospective Cohort Clinical Study with Objective Assessments
Location: London, UK
Cohort: 29 male and 17 female patients aged 26 to 70, 24 primary snorers (AHI<5) and 22 mild OSA (AHI 5-15), Average BMI 27
98% of patients achieved an average reduction of 44% in snoring time at greater than 40 decibels
The aim of this Prospective Cohort Clinical Study was to use objective measures and assess the reproducibility of the outcomes of the previous study at another independent facility. This was a prospective cohort study on individuals with Primary Snoring and/or Mild OSA (AHI <15).
The study assessed objective snoring (% time snoring) and respiratory parameters (AHI, RDI, Saturations) with two consecutive night sleep studies before and two consecutive night sleep studies after the use of the device. This was supplemented with bed partner VAS recordings and sleep quality questionnaires – Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI).
The Snoozeal® device was used for 20-minutes, once a day for a 6-week period.
Clinically proven objective improvement in snoring and mild OSA with the use of Snoozeal®
Average % reduction in AHI, ODI and ESS in patients with mild OSA pre and post-therapy with Snoozeal®
c.70% of patients responded to treatment with an average 47% reduction in AHI index
c.70% of patients responded to treatment with an average 41% reduction in ODI index
c.70% of patients responded to treatment with an average 43% reduction in ESS index
Reduction in snoring time at less than 40dB in patients pre and post-therapy with Snoozeal®
c.70% of patients achieved
30% TO 80% REDUCTION IN SNORING
Objective snoring reduced in
95% of patients with an average REDUCTION OF 48%
70% of partners reported an
average REDUCTION OF >50% in their partner’s snoring